Weekly Digest – January 2026 Weekly Digest – January 2026 05 January 2026: Kelun-Biotech announces Breakthrough Therapy Designation granted in China for Sacituzumab Tirumotecan (sac-TMT) in combination with immunotherapy Pembrolizumab for first-Line treatment of PD-L1-positive NSCLC The Company has reached […]
Weekly Digest – January 2026 Weekly Digest – January 2026 4 January 2026: Kelun-Biotech receives Investigational New Drug Approval for ITGB6-targeted ADC SKB105 from the NMPA Kelun-Biotech has achieved a key regulatory milestone with the approval of an Investigational New […]
Weekly Digest – January 2026 Weekly Digest – January 2026 8 January 2026: Whitehawk Therapeutics advances to clinical stage with IND clearance for HWK-007 and announces IND Submission for HWK-016 Whitehawk Therapeutics received FDA clearance for its PTK7-targeted ADC HWK-007, […]
Weekly Digest – January 2026 Weekly Digest – January 2026 7 January 2026: Lonza’s Synaffix and Sidewinder Therapeutics announce multi-target License agreement to advance development of next generation Bispecific ADCs Lonza (through its subsidiary Synaffix) and Sidewinder Therapeutics entered a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 7 January 2026: InduPro Therapeutics announces strategic collaboration with Lilly to develop first-in-class Bispecific/Multispecific oncology therapeutics using InduPro’s proximity-guided platform InduPro entered a global strategic collaboration, licensing agreement, and equity […]
Weekly Digest – January 2026 Weekly Digest – January 2026 6 January 2026: Convergent Therapeutics and NorthStar Medical Radioisotopes announce expanded partnership to support Convergent’s late-stage alpha-emitting radioantibody program Convergent Therapeutics and NorthStar Medical Radioisotopes expanded their partnership to co-locate […]
Weekly Digest – January 2026 Weekly Digest – January 2026 30 December 2025: CellBion seeks conditional approval for prostate cancer treatment candidate 177Lu-pocuvotide CellBion completed submission of a conditional approval application on December 30 to the Ministry of Food and […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 December 2025: Alphamab Oncology announces IND application for a Phase 3 clinical study of HER2 bispecific ADC subcutaneous co-formulation JSKN033 as first-line treatment of advanced cervical cancer was officially […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 December 2025: Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world Junshi Biosciences has recently registered a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 28 December 2025: Senhwa Biosciences aims at a multi-billion dollar global market with CX-5461 combined with ADC “blockbuster” therapy Senhwa Biosciences announced a Phase 1 clinical trial evaluating its first-in-class […]
